How ICER Builds a Value Assessment, Beyond the Price

The short answer

When the Institute for Clinical and Economic Review (ICER) publishes a value assessment of a new drug, the sticker price is the last thing it decides, not the first. The assessment runs on two engines: a lettered evidence rating that asks how certain we can be that the drug improves health compared with what patients already use, and a long-term cost-effectiveness model that asks what price would make that health gain a fair trade against everything else a health system could buy. Together they produce a value-based price range plus a separate check on whether a fair long-term price could still strain budgets in the short term.

This is educational, not medical advice, and nothing here endorses or discourages any specific treatment.

The evidence rating comes first

Before any dollar figure appears, ICER grades the clinical evidence using its Evidence Rating Matrix. The matrix, described on ICER's website and in the 2023 Value Assessment Framework, plots two questions at once: how large is the net health benefit versus a defined comparator, and how certain are we of that judgment. The output is a letter. An A ("Superior") means high certainty of a substantial net benefit; B ("Incremental") means high certainty of a small one; C ("Comparable") means high certainty the drug is about even with its comparator; D ("Negative") means high certainty it is worse.

When the data are thinner, the certainty axis takes over. Ratings such as B+, C+, and C++ signal moderate rather than high confidence, P/I ("Promising but Inconclusive") flags a drug that looks helpful but rests on immature evidence, and I ("Insufficient") marks cases where the evidence simply cannot support a confident call. ICER's own user guide notes the matrix descends from an evidence-based-medicine grid developed by a multi-stakeholder group. The practical point is that a drug can be genuinely effective and still earn a cautious letter because the trials were short, small, or lacked a real-world comparator.

Then the cost-effectiveness model

Only after the evidence is graded does ICER model long-term value. The core tool is the cost-effectiveness analysis, which estimates lifetime costs and lifetime health gains and expresses the result as a cost per quality-adjusted life year (QALY). ICER pairs the QALY with the equal value of life years gained (evLYG), a metric built partly in response to the criticism that QALYs can undervalue treatments for people with chronic illness or disability by counting their added life-years as worth less.

Those cost-per-health figures are then compared against willingness-to-pay thresholds. As the 2023 framework describes, ICER typically frames a health-benefit price benchmark as a range: a lower bound anchored near $100,000 per QALY gained and an upper bound near $150,000 per evLYG. Reading the benchmark backward from those thresholds gives the value-based price range, the prices at which the drug's cost would match its measured health benefit. This is where "beyond the price" becomes literal. The model does not ask what a company charges. It asks what a health system could justify paying for the health produced.

The short-term affordability check

Long-term value and short-term affordability are different problems, and ICER keeps them separate. Alongside the cost-effectiveness model sits a potential budget impact analysis. ICER sets an annual threshold tied to growth in the national economy, which it updated in October 2025 from about $880 million to roughly $821 million in new spending per year. When a drug's projected uptake would push spending past that line, the report flags a risk to short-term affordability and possible access barriers, even if the long-term price looks reasonable. A drug can be a fair value per patient and still overwhelm a budget if enough patients start it at once.

What the framework tries not to miss

A model built on averages will miss things, and the framework acknowledges as much through what it calls contextual considerations and potential other benefits. These include the severity of the illness, the value of hope for patients facing few options, effects on caregivers, and equity concerns. ICER also uses special adaptations for ultra-rare diseases and for one-time or short-course therapies whose costs and benefits land at very different moments. Many of these elements are described qualitatively rather than folded into the cost-per-QALY number, which is a deliberate signal that they matter even when they resist quantification.

The public deliberation

None of this is decided behind closed doors. As ICER's methods pages set out, an assessment moves through scoping, a draft evidence report open to public comment, and a revised report presented at a public meeting. There, one of ICER's independent appraisal committees deliberates and votes on the key questions, followed by a policy roundtable of clinicians, patient representatives, and payers who discuss how the findings might apply in practice. A final evidence report follows. The votes and ratings are recommendations meant to inform decisions, not binding rules.

What it can and cannot judge

Read this way, an ICER assessment is a structured argument, not a final grade. It can compare a drug to its alternatives, quantify uncertainty, and translate health gains into a defensible price range. It cannot capture every value that matters to a specific patient, and it depends on model assumptions and trial data that are only as good as the evidence available on the day it is written. The QALY itself remains contested, which is why the evLYG sits beside it. Understanding the machinery, the evidence letter, the cost-per-health model, the affordability flag, and the public vote, is what lets a reader judge the judgment rather than react to a single number.